Abstract
PurposeThis study was conducted to explore the diagnostic value of microRNA-143 (miRNA-143) in predicting in-stent restenosis (ISR) of lower extremity arterial occlusive disease (LEAOD).MethodsFrom February 2012 to March 2015, 165 patients (112 males and 53 females) with LEAOD undergoing interventional treatment were enrolled in this study. Serum miRNA-143 expression was detected using quantitative real-time polymerase chain reaction (qRT-PCR). Patients were assigned into the restenosis and non-restenosis groups according to routine surveillance postoperative angiography. A logistic regression analysis was conducted to analyze the risk factors for ISR in LEAOD patients. A receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of miRNA-143 in predicting ISR for LEAOD patients.ResultsThere were 74 and 91 patients in the restenosis and non-restenosis groups, respectively. Before the treatment, there were significant differences in history of diabetes, smoking status, blood sugar level (BSL) at admission, low-density lipoprotein cholesterol (LDL-C) level, and stent diameter between the restenosis and non-restenosis groups (all P < 0.05). Serum miRNA-143 expression was lower in the restenosis group than in the non-restenosis group (P < 0.05). Serum miRNA-143 expression in the restenosis group was correlated with smoking status, history of diabetes, BSL, and LDL-C (all P < 0.05). Logistic regression analysis demonstrated that miRNA-143, LDL-C, and smoking status were correlated with the postoperative ISR (all P < 0.05). ROC curve analysis revealed that the area under the curve (AUC) of miRNA-143 in predicting ISR for LEAOD patients was 0.866.ConclusionOur results indicate that miRNA-143 can be a promising tool for predicting the ISR in LEAOD patients.
Highlights
Lower extremity arterial occlusive disease (LEAOD), derived from atherosclerosis, is a vascular disease with a high incidence of coronary artery disease and even limb loss worldwide [1]
It has been discovered that Med Res (2017) 22:2MicroRNAs (miRNAs)-143, lying on human chromosome 5 (1.7 kb), and highly expressive in vascular smooth muscle cells (VSMCs), plays a crucial part in the migration and proliferation of VSMCs [11]
There were no significant differences in age, gender, hypertension, or hyperlipidemia between the two groups
Summary
Lower extremity arterial occlusive disease (LEAOD), derived from atherosclerosis, is a vascular disease with a high incidence of coronary artery disease and even limb loss worldwide [1]. Endovascular interventional treatment, with advanced techniques and devices, has been widely used in the treatment of artery occlusive disease [2, 3]. MicroRNAs (miRNAs) are a novel class of endogenous, non-protein coding, small RNA molecules that can modulate hundreds of genes [8]. Their altered levels have been reported in patients with various diseases, such as heart failure and coronary artery disease [9]. Several previous studies have been conducted to probe the expression of miRNAs in LEAOD [1, 13], few have reported details of the correlation between miRNA-143 and ISR in LEAOD. This study was conducted to provide a better solution to intervening in LEAOD with further insight into the molecule’s diagnostic value in predicting ISR based on its expression
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
